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ABSTRACT
Bloodstream infections caused by Candida spp. are increasingly recognised in critically ill adult and
paediatric individuals, with significant associated morbidity and mortality. Candida albicans is the single
most common fungal species to cause nosocomial infections. However, non-C. albicans spp., including
Candida glabrata and Candida krusei, which are less susceptible to fluconazole, have become more
common. Until the 1980s, the therapeutic possibilities for invasive candidosis were limited to
amphotericin B, but with the advent of new antifungal agents, such as azoles and echinocandins, less
toxic therapeutic options have become available and there are now possibilities for prevention and
optimised therapy for documented Candida infections. In this review, the currently available options for
the treatment of candidaemia and invasive candidosis are discussed with regard to the role of liposomal
amphotericin B in comparison with the echinocandins and azoles.
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INTRODUCTION
Bloodstream infections (BSIs) due to Candida spp.
are a major cause of morbidity and mortality in
hospitalised adults and children in many coun-
tries worldwide. The specific epidemiology with
regard to the incidence of candidaemia as well as
the distribution of Candida pathogens (Candida
albicans vs. non-C. albicans spp.) varies markedly
from country to country as well as from region to
region. The reasons for these variations are not
well understood. In some patient groups, such as
haematological patients with prolonged neutro-
penia, non-C. albicans spp. are detected much
more frequently than in non-neutropenic patients
in surgical intensive care units (ICUs). Non-
C. albicans spp. are more likely to occur in patients
who have received antifungal therapy with azoles
(e.g., fluconazole).
Data regarding sepsis in the USA showed that
between 1979 and 2000 there was an annual
increase in the incidence of sepsis of 8.7%, from
about 164 000 cases to nearly 660 000 cases.
Furthermore, the rate of sepsis due to fungi
increased by 207% [1]. The importance of fungi
as a cause of BSIs has been explored in a 6-year
population-based model. All patients (n = 1745)
with a nosocomial BSI identified between 1986
and 1991 at a single 900-bed tertiary-care hospital
were studied to identify microbiological factors
independently associated with mortality due to
infection [2]. According to this study, Candida spp.
were the only organisms that influenced inde-
pendently the outcome of nosocomial BSIs (OR
for mortality = 1.84).
In various studies, the attributable mortality
rate of candidaemia was estimated to be >30%,
together with a crude mortality rate of >50% [3–
5]. In most settings, the most frequently isolated
Candida species is C. albicans, although non-
C. albicans spp., such as Candida glabrata, Candida
parapsilosis and Candida tropicalis are being iso-
lated from blood cultures with increasing fre-
quency in Europe and the USA. Non-C. albicans
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spp. now account for approximately 50% of
isolates [6]. This review will focus on recent
developments in therapeutic options for invasive
candidosis including candidaemia.
CLINICAL SIGNIFICANCE OF
CANDIDA BLOODSTREAM
INFECTIONS
During the period 1980–1990, hospitals reporting
data to the CDC National Nosocomial Infections
Surveillance (NNIS) system reported a steady
increase in the rate of nosocomial fungal infec-
tions, from 2.0 to 3.8 per 1000 discharges. Among
NNIS hospitals, there was an increase from 5.4%
in 1980 to 9.9% in 1990 in the proportion of fungi
causing nosocomial BSIs [6]. Patients in neonatal,
surgical, haematological or burn units appeared
to be particularly at risk.
During the subsequent study period, it was
noted that in ICUs participating in the NNIS
system from 1989 to 1999, for the first time a
significant decrease in the incidence of Candida
BSI was found (p < 0.001). In this study, 1116
ICUs in which 2579 candidaemias were observed
were evaluated, and the incidence was calculated
to be 4.8 cases per 10 000 catheter days. Interest-
ingly, the decline was mainly due to a reduction
in the incidence of C. albicans BSI, from eight cases
per 10 000 catheter days (1989) to two cases per
10 000 catheter days in 1999. However, simulta-
neously, a significant increase in the incidence of
C. glabrata BSI was observed [7].
Owing to the different denominators (catheter
days, discharge from hospital or admission to the
ICU, etc.) among the various studies, it is often
difficult to compare the ‘true’ incidence rates of
candidaemia. Some studies show an overall trend,
with a decline in C. albicans fungaemia and a rise
in non-C. albicans fungaemias, whereas others do
not [7–14]. In order to calculate the incidence of
candidaemia, it appears reasonable to avoid study
of a general population with a huge proportion of
patients at low risk for invasive candidosis. In
these studies, the rate of candidaemias per 1000
admissions was calculated to be maximally 0.07
[11]. In contrast, studies in units with a high
number of patients at high risk for invasive
candidosis show much higher incidence rates.
Rates above 20 candidaemias per 1000 admissions
have been observed in some regions of the world,
e.g., Taiwan [10]. Owing to this constellation,
direct comparisons of incidence rates among
studies of different patient populations are not
helpful in proving that rates are either increasing
or declining. It appears more appropriate to
describe a particular high-risk patient group in a
study centre and to follow this population longi-
tudinally over time. The most reliable data may
be derived from the study by Martin et al., who
demonstrated over a 22-year period that the rate
due to fungal sepsis increased by 207%, namely
from 5132 cases in 1979 to 16 042 cases in 2000 [1].
THERAPY OF CANDIDAEMIA AND
INVASIVE CANDIDA INFECTIONS
The optimal treatment strategy for serious Can-
dida infections remains controversial. Conven-
tional amphotericin B deoxycholate (cAmB-D)
has served as the standard treatment for five
decades, but its toxicity and limited efficacy have
underscored the need for alternative antifungal
drugs. Fluconazole is as effective as amphoteri-
cin B for the treatment of candidaemia, with
superior safety, although the reduced susceptibil-
ity of some species, such as C. glabrata and
Candida krusei, may limit its use in settings where
these species are prevalent. Newer options for
patients with candidaemia or invasive candidosis
include broad-spectrum azoles, such as vorico-
nazole, and the echinocandins (caspofungin, mi-
cafungin and anidulafungin). Most importantly,
starting antifungal therapy in a compromised
patient with candidaemia immediately after
receipt of the culture results from the laboratory
is mandatory to improve overall survival [15].
Large randomised studies have been under-
taken to compare these new agents with existing
treatment regimens. In the first, caspofungin was
compared with amphotericin B; the second com-
pared voriconazole with a short course of ampho-
tericin B followed by fluconazole; and, most
recently, anidulafungin has been compared with
fluconazole, whereas micafungin was tested
against both liposomal amphotericin B (L-AmB)
and caspofungin [16–20].
Azoles
Fluconazole.
In the first landmark study with regard to the
treatment of candidaemia, a multicentre rando-
mised trial that compared cAmB-D with
Ruhnke et al. Treatment of candidaemia 47
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 4), 46–54
fluconazole as treatment for candidaemia, non-
neutropenic patients were randomly assigned to
receive either amphotericin B (0.5–0.6 mg ⁄ kg
body weight ⁄day) or fluconazole (400 mg ⁄day),
each to be continued for at least 14 days after the
last positive blood culture [21]. Two hundred and
thirty-seven patients were enrolled; the most
common underlying diagnoses were renal failure,
non-haematological cancer, and gastrointestinal
disease. There was no statistically significant
difference in outcome; of the 103 patients treated
with cAmB-D, 81 (79%) were judged to have
been treated successfully, as were 72 of the 103
patients treated with fluconazole (70%). The BSI
failed to clear in 12 patients in the amphotericin
group and 15 in the fluconazole group; C. albicans
was the species most commonly associated with
failure. There were 41 deaths in the cAmB-D
group and 34 deaths in the fluconazole group
[21].
The second study had a similar design (a
randomised, blinded, multicentre trial) and com-
pared fluconazole (800 mg ⁄day) plus placebo
with fluconazole plus cAmB-D (0.7 mg ⁄kg ⁄day)
as therapy for candidaemia due to species other
than C. krusei in adults without neutropenia [22]
The placebo ⁄ cAmB-D component was intended
to be given for the first 5–6 days only. In total, 219
patients were evaluated. Overall success rates
were 56% (60 of 107 patients) and 69% (77 of 112
patients; p 0.043), respectively; the BSI failed to
clear in 17% and 6% of subjects, respectively
(p 0.02). It was concluded from this study that in
non-neutropenic subjects, the combination of
fluconazole plus cAmB-D was not antagonistic
as compared with fluconazole alone. In addition,
with the combination, a trend towards improved
success and more rapid clearance from the blood-
stream was seen [22].
As compared to the study by Rex and col-
leagues, the higher dosage of fluconazole
(800 mg ⁄day) appeared not to be superior, but it
is nevertheless recommended by some experts
instead of the standard dose of 400 mg ⁄day
assuming better coverage against organisms with
reduced susceptibility [23,24].
Fluconazole may be the drug of first choice in
clinically stable patients who are not on azole
prophylaxis and with proven fluconazole-suscep-
tible Candida spp., and is recommended in most
current guidelines [25–27]. However, the utility of
fluconazole as initial therapy for unspeciated
Candida isolates is limited by its reduced activity
against some species, in particular C. glabrata,
which has become more prevalent in many
settings. Thus, initial broad-spectrum therapy
has become a standard approach, especially in
unstable patients, with subsequent step-down to
safe and ⁄ or oral agents once the isolate has been
identified and its susceptibility has been deter-
mined.
Itraconazole.
Data about itraconazole for treatment of candid-
aemia are very limited. One study has been
published as a congress report [28]. One hundred
and ninety patients were randomly assigned to
receive either intravenous itraconazole, followed
by itraconazole oral solution for the treatment of
candidaemia in non-neutropenic patients, or
fluconazole. Intravenous itraconazole 200 mg
was given twice daily on days 1 and 2, and
thereafter once daily for 5 days (and for a further
7 days if the patient appeared to be non-compli-
ant with oral medication); subsequently, itraco-
nazole oral solution 200 mg twice-daily was given
until 14 days after resolution of symptoms and
signs of fungal infection and negative cultures.
Intravenous fluconazole 400 mg was given once
daily for at least 7 days, followed by once daily
fluconazole 400 mg orally until 14 days after
resolution of infection and negative cultures.
The study was terminated prematurely because
of the very slow enrolment rate after 197 patients
had been randomised (n = 99 itraconazole and
n = 98 fluconazole). Only 37 patients who had
received itraconazole and 44 patients who had
received fluconazole could be evaluated for
primary efficacy. At the week 12 follow-up time-
point, itraconazole had a success rate of 92% (34
of 37 patients), as compared with 91% for fluco-
nazole (40 of 44 patients). It should be noted that
intravenous itraconazole has been withdrawn in
the USA.
Similar, small studies have been performed in
paediatric patients with candidaemia [29,30]. In
India, 37 patients were treated with itraconazole
(10 mg ⁄ kg ⁄day orally or through a gastric tube).
Thirty (81%) patients recovered; on average,
microbiological cure was noted by day 14 (range
4–30 days). The mean duration of therapy in
patients who responded was 24 ± 7 days (range
21–42 days). Major side-effects were not reported.
In a second study, also published in abstract form
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only, 43 patients received either fluconazole
(n = 22) or itraconazole (n = 21) orally or through
a gastric tube at a dose of about 10 mg ⁄ kg. The
cure rate was similar in both the groups: for
itraconazole, 17 of 21 (81%), and for fluconazole,
18 of 22 (82%). The crude mortality rate
(itraconazole 9.5% and fluconazole 13.6%) was
also comparable in both patient groups.
In general, there is only poor evidence to justify
use of itraconazole for this indication.
Voriconazole.
Voriconazole has been shown to be as effective
as and less toxic than the regimen of cAmB-D
followed by fluconazole in the treatment
of candidaemia in non-neutropenic patients
[16]. Four hundred and twenty-two non-neu-
tropenic patients were randomised 1:2 to either
voriconazole (3 mg ⁄ kg, intravenous, twice-daily,
or 200 mg ⁄day oral maintenance doses) or
a strategy of intravenous amphotericin B (0.7–
1.0 mg ⁄kg ⁄day) followed by fluconazole
(400 mg ⁄day), after 3–7 days. In the primary
analysis, the proportion with sustained success-
ful outcomes at 12 weeks after the end of
therapy was 40.7% in both treatment arms,
demonstrating the non-inferiority of voriconaz-
ole as compared to the standard treatment
regimen. Successful response rates were also
comparable (65% vs. 71%, p 0.25) at the last
evaluable time-point (end of therapy (EOT) or 2,
6 or 12 weeks after EOT), and at the end of
study drug therapy (70% vs. 74%, p 0.42).
Voriconazole cleared blood cultures as quickly
as cAmB-D ⁄fluconazole sequential therapy.
There were significantly fewer severe clinical
adverse events or laboratory abnormalities in
patients who received voriconazole than in
those who had been treated with amphoteri-
cin B followed by fluconazole. Stepping down to
oral voriconazole was feasible in most patients
and led to serum concentrations comparable to
those obtained with intravenous voriconazole
(Kullberg, personal communication). This study
underscored the concept that an early step-
down to oral voriconazole is effective in many
patients. Voriconazole has a broad spectrum of
activity (largely deduced from in-vitro studies;
only a limited number of in-vivo studies
are available). However, voriconazole is associ-
ated with a number of side-effects and drug
interactions.
Posaconazole.
There are insufficient data to evaluate posacona-
zole in the treatment of invasive candidosis or
candidaemia, but the compound shows good
microbiological efficacy against Candida spp.
in vivo as well as being clinically tolerable as
compared to fluconazole in the treatment of
patients with HIV ⁄AIDS who suffer from oro-
pharyngeal candidosis [31].
AMPHOTERICIN B AND LIPID
FORMULATIONS
cAmB-D
As shown above, randomised studies did not
demonstrate any superiority of cAmB-D over
fluconazole or voriconazole [16,21,22,32–35]. The
major disadvantages of cAmB-D include nephro-
toxicity, electrolyte disturbances and acute infu-
sion-related side-effects. An increasing number of
publications have reported serious long-term
nephrotoxicity with the use of cAmB-D that
interfered with potentially nephrotoxic medica-
tions, especially in stem-cell-transplanted
patients, with inferior survival as a direct conse-
quence [36–39]. In the update of the Infectious
Diseases Society of America (IDSA) guidelines,
cAmB-D is no longer recommended as the drug of
first choice for invasive Candida infections, mainly
because much safer drugs that have demon-
strated at least similar efficacy are now available
[27,32,40]. Therefore, cAmB-D should no longer
be recommended for routine use, except for the
treatment of special forms of invasive candidosis
(e.g. Candida endocarditis or meningitis) where
no data from randomised trials are available
and under conditions for which there are limited
financial resources [27].
Amphotericin B lipid formulations
As compared to cAmB-D, the lipid formulations
offer similar efficacy and significantly better
tolerability. Both amphotericin B lipid complex
(ABLC) and L-AmB are licensed for second-line
therapy of invasive Candida infections.
It has been shown in an emergency use study
and in a large mycoses database (CLEAR regis-
try) that ABLC is effective as second-line therapy
for invasive candidosis [41]. A randomised
study that compared ABLC with cAmB-D in a
Ruhnke et al. Treatment of candidaemia 49
 2008 The Authors
Journal Compilation  2008 European Society of Clinical Microbiology and Infectious Diseases, CMI, 14 (Suppl. 4), 46–54
population that included neutropenic patients
has shown similar efficacy and better tolerability
of ABLC in comparison with the conventional
formulation, but the study results have not been
published (35th ICAAC, abstract LM21).
Studies on salvage treatment and randomised
comparisons between cAmB-D and L-AmB were
only concerned with a cohort of patients with
mixed invasive mycoses, and the study popula-
tions contained only a few patients who suffered
from invasive candidosis. An analysis of eight
open-label studies on conventional amphoteri-
cin B and amphotercin B lipid formulations
showed an efficacy rate of 75% for those on
ABLC and 80% for L-AmB-treated patients with
candidosis [42]. A recently published study that
compared L-AmB with micafungin (see below) as
first-line treatment demonstrated a high efficacy
of L-AmB in the treatment of invasive Candida
infections [17]. Therefore, L-AmB may be consid-
ered as a reliable alternative to caspofungin,
fluconazole or voriconazole for treatment of inva-
sive Candida infections, in particular where the
pathogen has been identified and is not covered
effectively by azoles or candins. The 2007 update
of the ECIL Guidelines for Antifungal Therapy in
Leukemia Patients has given L-AmB the highest
recommendation (A1), similar to that for caspo-
fungin, where the species had been identified.
Echinocandins
Echinocandins (caspofungin, micafungin, anidu-
lafungin) belong to a new class of antifungals that
act as fungal cell-wall b-(1,3)-D-glucan synthase
enzyme complex inhibitors. Caspofungin was the
first of the echinocandins to receive approval for
the treatment of patients with invasive aspergil-
losis who were not responding to or intolerant of
other antifungal therapies, and was subsequently
licensed for the treatment of patients with candi-
daemia and invasive candidosis as well. Recently,
data from two prospective randomised trials that
compared micafungin with L-AmB, and anidula-
fungin with fluconazole, respectively, for treat-
ment of invasive candidosis and candidaemia
have been published [17,20]. In the most recent
update of the IDSA guidelines, all three echino-
candins (anidulafungin, caspofungin, micafun-
gin) are labelled as equally effective for the
treatment of candidaemia and invasive candido-
sis.
Caspofungin.
Caspofungin has been shown to be as effective as
amphotericin B for the treatment of invasive
candidosis and candidaemia in adult patients,
with fewer treatment-related adverse events [18].
This trial showed for the first time the high
efficacy of an echinocandin antifungal agent in
patients with candidaemia or invasive candidosis.
Two hundred and thirty-nine patients with can-
didaemia and invasive candidosis were rando-
mised 1:1 to receive intravenous caspofungin
(70 mg loading, 50 mg ⁄day maintenance dose)
or intravenous cAmB-D (0.6–1.0 mg ⁄kg ⁄day). The
primary efficacy analysis was the overall response
at the end of intravenous therapy in the modified
intend-to-treat (MITT) population. Patients were
also assessed on day 10 of therapy and at the end
of all therapy. Similar proportions of patients in
both treatment arms had successful outcomes at
the end of therapy (73.4% for caspofungin; 61.7%
for cAmB-D). There were significantly fewer
drug-related adverse events and discontinuations
in the caspofungin arm than in the cAmB-D arm
[18].
A recent trial has been reported in patients
with documented invasive candidosis who
received their first dose of the study drug in
the ICU setting as compared with those outside
the ICU as part of a double-blind randomised
trial [44]. Patients received caspofungin
(50 mg ⁄day after a 70-mg loading dose) or
cAmB-D (0.6–1.0 mg ⁄kg ⁄day) for 10–14 days. Of
the 224 patients, 97 (43%) received their first dose
of the study drug in the ICU. Candidaemia was
demonstrated in 81% of ICU patients and in 84%
of non-ICU patients. Favourable response rates in
the ICU patients as compared to the non-ICU
patients were 68% vs. 77% for caspofungin and
56% vs. 67% for cAmB-D, respectively. After
accounting for differences in APACHE II score,
neutropenia status, and geographical region, it
was found that patients who commenced therapy
with the study drug in an ICU were more likely
to die than patients who started therapy with the
study drug outside an ICU. For ICU patients, all-
cause mortality rates were 45% for caspofungin
recipients and 40% for cAmB-D recipients. Can-
dida-associated mortality rates were 5% for ca-
spofungin recipients and 11% for cAmB-D
recipients. Drug-related adverse events were
reported less often among the ICU patients than
among the non-ICU patients.
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Owing to its efficacy and spectrum of activity,
which extends to non-C. albicans spp., as well as
its good safety profile, caspofungin may be
regarded as a first-choice drug for severely ill,
clinically unstable patients with organ dysfunc-
tion, especially patients with neutropenia.
Micafungin.
In a large prospective trial, micafungin was
compared with L-AmB for first-line therapy of
invasive candidosis and candidaemia [17]. In this
phase III, 1:1 randomised, double-blind, non-infe-
riority study, adult patients with confirmed
invasive candidosis received micafungin
(100 mg ⁄day) or L-AmB (3 mg ⁄ kg ⁄day). Treat-
ment success was defined as clinical response
combined with mycological response at the end of
therapy. Five-hundred and thirty-one patients
received at least one dose of the study drug: 264
and 267 patients in the micafungin and L-AmB
groups, respectively. The per-protocol set analysis
included 202 and 190 patients, respectively. Can-
didaemia was established in 84.2% of patients
who were treated with micafungin and in 85.8%
of those on L-AmB. Non-C. albicans infections
constituted 62.4% and 58.9% of patients, respec-
tively (per-protocol set analysis). Overall success
at EOT was 89.6% for micafungin and 89.5% for
L-AmB, respectively. Predefined safety parame-
ters showed micafungin to have advantages over
L-AmB with regard to renal function, as assessed
by an estimated glomerular filtration rate, and the
drug showed a lower incidence of infusion-
related reactions (p < 0.001). Efficacy was inde-
pendent of the Candida species, primary site of
infection, neutropenic status, APACHE II score,
and whether or not a catheter was removed or
replaced during the study. The authors concluded
that, there being no difference between the treat-
ment groups, micafungin was as effective as L-
AmB as first-line treatment for both C. albicans
and non-C. albicans candidaemia and invasive
candidosis.
Most recently, a trial comparing micafungin
with caspofungin as first-line therapy for invasive
candidosis and candidaemia was published [19].
In an international, randomised, double-blind
three-arm trial, adult patients with candidaemia
and other forms of invasive candidosis were
randomised to receive micafungin (group 1,
100 mg daily) or micafungin (group 2, 150 mg
daily) or caspofungin (group 3, 70-mg starting
dose followed by 50 mg daily). In total, 595
patients were randomised to one of the three
treatment groups and they received at least one
dose of the study drug. In the MITT population,
191 patients were assigned to the micafungin 100-
mg group, 199 to the micafungin 150-mg group,
and 188 to the caspofungin group. Approximately
85% of patients had candidaemia; the remainder
had other forms of invasive candidosis. At the
end of intravenous therapy, treatment was con-
sidered successful for 76.4% of patients in the
micafungin 100-mg group (group 1), 71.4% in the
micafungin 150-mg group (group 2), and 72.3%
in the caspofungin group. The median time to
sterilisation of the cultures was 2 days for group 1
and group 3, as compared with 3 days for those
on micafungin 150 mg. There were no significant
differences in rates of mortality, relapsing and
emerging infections or adverse events between
the study arms. Importantly, a loading dose is
apparently not needed with micafungin, in
contrast to the other echinocandins.
Micafungin may be regarded as an alternative
to caspofungin and anidulafungin as a drug of
first choice for severely ill, clinically unstable
patients with organ dysfunction, especially those
with neutropenia.
Anidulafungin.
In a recent study, anidulafungin was shown to be
superior to fluconazole in the treatment of adult
patients with invasive candidosis or candidaemia,
whereas the safety profile appeared to be similar
[20]. Two hundred and sixty-one adult patients
with invasive Candida infections were randomly
assigned to receive either anidulafungin or fluco-
nazole intravenously. All patients could be
switched to oral fluconazole after 10 days of
intravenous therapy. The primary efficacy analy-
sis concerned a global response in the MITT
population at the end of therapy. Patients were
also assessed at 2 and 6 weeks, and after the end
of therapy.
Of the 245 patients in the primary analysis, 89%
had candidaemia only. C. albicans was isolated
from 62% of the 245 patients. Most of the patients
(97%) did not have granulocytopenia. At the end
of intravenous therapy, treatment was deemed
successful in 75.6% of patients treated with
anidulafungin, as compared with 60.2% of those
treated with fluconazole. The results were similar
for other endpoints of efficacy. The publication
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caused substantial debate, as it was suggested
that the advantage (potential superiority) of ani-
dulafungin over fluconazole was based on the
data from a single centre that had contributed a
large number of patients who had a poor outcome
when treated with fluconazole. However, the
statistical analyses failed to show a ‘centre effect’.
When data from the site that enrolled the largest
number of patients were removed, success rates at
the end of intravenous therapy were 73.2% for the
anidulafungin group and 61.1% for the flucona-
zole group. Safety was comparable in the two
arms. The death rate from all causes was 31% in
the fluconazole group and 23% in the anidula-
fungin group (p not significant (NS)), respec-
tively.
From this trial, it may be concluded that
anidulafungin showed at least non-inferiority in
comparison with fluconazole and its use was
associated with higher clinical efficacy and
enhanced clearance of Candida spp. from the
bloodstream as compared to fluconazole.
COMBINATION THERAPY
The potential benefit of a combination of cAmB-D
and flucytosine as antifungal therapy has not
been studied in large randomised trials other than
the classic trial on the treatment of cryptococcosis.
In spite of the lack of evidence, it appears
reasonable to consider the simultaneous use of
two drugs in cases of particular defined organ
manifestations such as endophthalmitis, peritoni-
tis, meningitis or endocarditis [31]. In a study by
Rex and colleagues, it was demonstrated that in
non-neutropenic subjects, the combination of
cAmB-D for 5–6 days and high-dose fluconazole
(800 mg) was not antagonistic when compared to
fluconazole alone, as success rates on day 30 did
not differ significantly [22]. However, use of the
combination was associated with an improved
overall clinical outcome, and showed more rapid
eradication of yeasts from the bloodstream as well
as a clear trend towards a higher success rate on
day 30 (57% for the fluconazole group vs. 69%
for the fluconazole plus cAmB-D group; p NS).
This improvement, in conjunction with a more
rapid mycological response, was accompanied
by significantly higher nephrotoxicity in the
combination arm (3% vs. 23%, p < 0.001). In
addition, as shown in a Kaplan–Meier analysis,
the beneficial effect of the combination of
cAmB-D plus fluconazole could be demon-
strated in patients with an intermediately high
APACHE II score but not for patients with a
high APACHE II score (>25). Overall mortality
rates were not different between the two study
regimens.
Efungumab (Mycograb) is a human recombi-
nant monoclonal antibody against heat-shock
protein 90 that has been shown to act synergisti-
cally against a wide array of Candida spp. when
added to amphotericin B [40]. A double-blind,
randomised study was conducted to determine
whether lipid-associated amphotericin B (either
ABLC or L-AmB) plus efungumab was superior
to lipid-associated amphotericin B plus placebo in
patients with culture-confirmed invasive candi-
dosis [44]. After stratification for the possible
occurrence of non-C. albicans spp., patients
received the lipid-associated amphotericin B plus
a 5-day course of efungumab or placebo. The
primary efficacy variable was the overall response
to treatment (clinical and mycological resolution)
by day 10. Of the 139 patients enrolled, 117 were
included in the MITT population. A complete
overall response by day 10 was obtained for 29
(48%) of 61 patients in the L-AmB ⁄ABLC group,
as compared with 47 (84%) of 56 patients in the
efungumab combination therapy group
(p < 0.001). Superiority of the combination was
shown for both clinical response (52% vs. 86%;
p < 0.001) and mycological response (54% vs.
89%; p < 0.001). The Candida-attributable mortal-
ity rate (18% vs. 4%; p 0.025) 4 weeks after
completion of study treatment and the rate of
culture-confirmed clearance of the infection
favoured the efungumab combination therapy
group as well. The interesting results from the
efungumab study need to be confirmed in
further trials. Efungumab (Mycograb) was re-
jected for licensing in Europe by the European
Medicines Agency for reasons that concerned
improvement of the manufacturing process of
the monoclonal antibody; the drug is not yet
available.
With regard to the current data, combination
therapy may be an alternative for certain patients
or in distinct forms of invasive Candida infections
but is not generally recommended. Indeed, sig-
nificant advantages, such as a reduction of overall
or attributable mortality rates due to invasive
candidosis or candidaemia, have not been shown
in other randomised trials.
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CONCLUSION
The armentarium of antifungal agents to combat
candidaemia and invasive Candida infections has
been extended in recent years. Considerable
improvements have been achieved with the intro-
duction of new drugs such as the echinocandins
with better drug safety, superior pharmacokinetic
properties and fewer drug–drug interactions.
Fluconazole remains the drug of choice for the
majority of patients with uncomplicated C. albi-
cans infections. However, it may be concluded
that the echinocandins have been established as
highly effective and safe alternatives to conven-
tional amphotericin B or azole antifungals, and
they (e.g., anidulafungin) may even be superior to
fluconazole with regard to clinical efficacy. Lipo-
somal amphotericin has been shown to be effec-
tive as well as less nephrotoxic than cAmB-D, but
the drug carries a higher risk of nephrotoxicity
than does micafungin. The design of the various
clinical trials differed among the published can-
didaemia studies, which makes a head-to-head
comparison of the results rather difficult. More-
over, the majority of candidaemia studies on
newer antifungals have used conventional
amphotericin B as the comparator. The currently
available echinocandins appear to be at least as
effective as conventional and liposomal ampho-
tericin B. Conventional amphotericin B can no
longer be recommended as the drug of first choice
for the treatment of invasive Candida infections
or candidaemia and should be reserved for
specific indications or under resource-limited
conditions.
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